Antifungal market decline
Executive Summary
Antifungal market depression could last nine months following FDA public health advisory associating Novartis' Lamisil and Janssen's Sporanox oral antifungals with liver problems, Novartis' Costa says. "The combined warnings have depressed the market and the market is now tracking below last year's." The May FDA advisory "for Lamisil was just a reaffirmation of what we had in our label of the need to monitor liver enzymes," Costa maintains